In the United States,<unk>  is indicated to treat moderate to severe persistent asthma, nasal polyps, and chronic idiopathic urticaria. In the European Union,<unk>  is indicated to treat allergic asthma, chronic (long-term) spontaneous urticaria (itchy rash), and severe chronic rhinosinusitis with nasal polyps. In Australia,<unk>  is indicated to treat allergic asthma and chronic spontaneous urticaria. Allergic asthma<unk>  is used to treat people with severe, persistent allergic asthma, uncontrollable with oral or injectable corticosteroids. Those patients have already failed step I to step IV treatments and are in step V of treatment. Such a treatment scheme is consistent with the widely adopted guidelines for the management and prevention of asthma, issued by Global Initiative of Asthma (GINA), which was a medical guidelines organization launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization. Chronic spontaneous urticaria<unk>  is indicated for chronic spontaneous urticaria in adults and adolescents (>12 years old) poorly responsive to H1-antihistamine therapy. When administered subcutaneously once every four weeks,<unk>  has been shown to significantly decrease itch severity and hive count.
Omalizumab
Crizanlizumab
Reslizumab
Lirentelimab
Tildrakizumab
Risankizumab
Bebtelovimab
Brolucizumab